Resources from the same session
VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
Presenter: Robert Coleman
Session: Presidential Symposium I
Resources:
Abstract
Presentation
Webcast
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Presenter: Isabelle Ray-Coquard
Session: Presidential Symposium I
Resources:
Abstract
Presentation
Webcast
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
Presenter: Suresh Ramalingam
Session: Presidential Symposium I
Resources:
Abstract
Presentation
Webcast
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis
Presenter: Solange Peters
Session: Presidential Symposium I
Resources:
Abstract
Presentation
Webcast
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)
Presenter: Antonio González Martín
Session: Presidential Symposium I
Resources:
Abstract
Presentation
Webcast
Invited Discussant LBA4_PR
Presenter: Sanjay Popat
Session: Presidential Symposium I
Resources:
Presentation
Webcast
Invited Discussant LBA3
Presenter: Mansoor Raza Mirza
Session: Presidential Symposium I
Resources:
Presentation
Webcast
Invited Discussant LBA1 and LBA2_PR
Presenter: Ana Oaknin
Session: Presidential Symposium I
Resources:
Presentation
Webcast